Insilico Medicine and Servier Announce Up to $888 Million AI-Driven Oncology R&D Collaboration
Insilico Medicine announced a multi-year R&D collaboration with Servier on January 4, 2026, valued at up to US$888 million for oncology drug discovery.
Insilico will use its proprietary Pharma.AI platform to identify and advance drug candidates for challenging oncology targets.
Insilico is eligible for up to US$32 million in upfront and near-term R&D payments; Servier will share R&D costs and lead clinical validation and commercialization.
The partnership combines Insilico's AI expertise with Servier's cancer drug development experience.
Insilico's oncology pipeline includes ISM6331 (pan-TEAD inhibitor) and ISM3412 (MAT2A inhibitor), both in Phase I trials.